Twist Bioscience Corporation (NASDAQ:TWST) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Twist Bioscience Corporation (NASDAQ:TWST) have been assigned an average rating of “Moderate Buy” from the ten research firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $98.30.

A number of analysts recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Wednesday, June 24th. UBS Group set a $89.00 target price on Twist Bioscience in a report on Monday, June 15th. Robert W. Baird increased their price target on Twist Bioscience from $113.00 to $115.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. Evercore downgraded shares of Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price objective for the company. in a research report on Monday, July 6th. Finally, Barclays lifted their target price on Twist Bioscience from $65.00 to $95.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 24th.

Insider Activity at Twist Bioscience

In other news, insider Dennis Cho sold 14,205 shares of the stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $89.75, for a total transaction of $1,274,898.75. Following the transaction, the insider owned 105,141 shares of the company’s stock, valued at approximately $9,436,404.75. This trade represents a 11.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Adam Laponis sold 2,399 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $94.33, for a total value of $226,297.67. Following the sale, the chief financial officer owned 110,276 shares in the company, valued at $10,402,335.08. The trade was a 2.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 151,529 shares of company stock worth $17,708,772. Company insiders own 3.08% of the company’s stock.

Institutional Trading of Twist Bioscience

Several hedge funds have recently made changes to their positions in TWST. Quarry LP bought a new stake in Twist Bioscience in the third quarter valued at $28,000. Western Wealth Management LLC bought a new stake in shares of Twist Bioscience during the 1st quarter worth about $31,000. Strs Ohio acquired a new stake in Twist Bioscience in the first quarter worth approximately $33,000. Strategic Advocates LLC lifted its holdings in shares of Twist Bioscience by 562.7% in the fourth quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock valued at $34,000 after buying an additional 906 shares during the period. Finally, SBI Securities Co. Ltd. lifted its holdings in Twist Bioscience by 68.9% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock valued at $44,000 after acquiring an additional 571 shares during the last quarter.

Twist Bioscience Stock Up 1.7%

Shares of NASDAQ TWST opened at $125.21 on Thursday. Twist Bioscience has a 12-month low of $23.30 and a 12-month high of $125.66. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. The firm’s 50-day moving average is $92.54 and its two-hundred day moving average is $66.21. The company has a market capitalization of $7.85 billion, a PE ratio of -56.40 and a beta of 2.14.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). The company had revenue of $118.38 million for the quarter, compared to analyst estimates of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. Twist Bioscience’s quarterly revenue was up 23.2% compared to the same quarter last year. During the same quarter last year, the company posted $0.33 EPS. Equities analysts anticipate that Twist Bioscience will post -2.12 EPS for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.